Monitoring through voriconazole plasma concentrations in haematological patients: real life multicentre experience

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F12%3A%230001663" target="_blank" >RIV/65269705:_____/12:#0001663 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1111/j.1439-0507.2012.02186.x" target="_blank" >http://dx.doi.org/10.1111/j.1439-0507.2012.02186.x</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/j.1439-0507.2012.02186.x" target="_blank" >10.1111/j.1439-0507.2012.02186.x</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Monitoring through voriconazole plasma concentrations in haematological patients: real life multicentre experience

Popis výsledku v původním jazyce

The objective of this retrospective study was to evaluate results from voriconazole therapeutic drug monitoring (TDM) in haematological patients in routine clinical practice. Between 2005 and 2010, 1228 blood samples were obtained from 264 haematologicalpatients receiving voriconazole for targeted/preemptive treatment of invasive aspergillosis (IA), empirical therapy or prophylaxis. A high-pressure liquid chromatography assay was used to analyse voriconazole concentrations. Clinical and laboratory datawere analysed retrospectively. With the exception of omeprazole administration, there was no relevant relationship between measured voriconazole concentrations and drug dose, route administration, age, gender, CYP2C19*2 genotype, gastrointestinal tractabnormality, administration via nasogastric tube, serum creatinine, and liver enzymes. However, per patient analysis identified significant role of individual voriconazole dose and drug form change on measured plasma concentration. Measur

Název v anglickém jazyce

Monitoring through voriconazole plasma concentrations in haematological patients: real life multicentre experience

Popis výsledku anglicky

The objective of this retrospective study was to evaluate results from voriconazole therapeutic drug monitoring (TDM) in haematological patients in routine clinical practice. Between 2005 and 2010, 1228 blood samples were obtained from 264 haematologicalpatients receiving voriconazole for targeted/preemptive treatment of invasive aspergillosis (IA), empirical therapy or prophylaxis. A high-pressure liquid chromatography assay was used to analyse voriconazole concentrations. Clinical and laboratory datawere analysed retrospectively. With the exception of omeprazole administration, there was no relevant relationship between measured voriconazole concentrations and drug dose, route administration, age, gender, CYP2C19*2 genotype, gastrointestinal tractabnormality, administration via nasogastric tube, serum creatinine, and liver enzymes. However, per patient analysis identified significant role of individual voriconazole dose and drug form change on measured plasma concentration. Measur

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Mycoses

ISSN

0933-7407

e-ISSN

—

Svazek periodika

55

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

10

Strana od-do

483-492

Kód UT WoS článku

000309888700003

EID výsledku v databázi Scopus

—